TB dosing gets a custom fit: new study tests precision medicine

NCT ID NCT06585358

Recruiting now Knowledge-focused Sponsor: Karolinska Institutet Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether using computer models to personalize tuberculosis (TB) drug doses can help patients reach optimal drug levels faster. Researchers will monitor 30 adults with pulmonary TB who are already on standard treatment. The goal is to see if this approach helps doctors adjust doses quickly and accurately, potentially improving treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: model-informed precision dosing (MIPD) for rifampicin, isoniazid, pyrazinamide, and ethambutol
What this could lead to: If successful, this could help doctors personalize TB drug doses for each patient, potentially improving treatment effectiveness and reducing side effects.
What could go wrong: This is a small, early observational study (30 people) that only tests whether the dosing method works in practice, not whether it improves cure rates. It may not lead to better outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS, PULMONARY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS, PULMONARY

Contacts and locations

Locations

Karolinska University Hospital
RECRUITING

Stockholm, 17177, Sweden
Linköping University Hospital
RECRUITING

Linköping, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.